These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 7548635)

  • 1. Structure-activity relationship studies of CNS agents. XII. 1-[4-(4-aryl-1-piperazinyl)butyl]-3,4-dihydro-2(1H)-quinolinones: new 5-HT1A, 5-HT2 and D2 ligands with a potential antipsychotic activity.
    Mokrosz JL; Chojnacka-Wójcik E; Dereń-Wesołek A; Kłodzińska A; Maćkowiak M; Bielecka Z; Paluchowska MH
    Drug Des Discov; 1994 Apr; 11(3):197-203. PubMed ID: 7548635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents.
    Campiani G; Butini S; Fattorusso C; Catalanotti B; Gemma S; Nacci V; Morelli E; Cagnotto A; Mereghetti I; Mennini T; Carli M; Minetti P; Di Cesare MA; Mastroianni D; Scafetta N; Galletti B; Stasi MA; Castorina M; Pacifici L; Vertechy M; Di Serio S; Ghirardi O; Tinti O; Carminati P
    J Med Chem; 2004 Jan; 47(1):143-57. PubMed ID: 14695828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological profiles in rats of novel antipsychotics with combined dopamine D2/serotonin 5-HT1A activity: comparison with typical and atypical conventional antipsychotics.
    Bardin L; Auclair A; Kleven MS; Prinssen EP; Koek W; Newman-Tancredi A; Depoortère R
    Behav Pharmacol; 2007 Mar; 18(2):103-18. PubMed ID: 17351418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serotonin 5-HT2 receptor, dopamine D2 receptor, and alpha 1 adrenoceptor antagonists. Conformationally flexible analogues of the atypical antipsychotic sertindole.
    Andersen K; Liljefors T; Hyttel J; Perregaard J
    J Med Chem; 1996 Sep; 39(19):3723-38. PubMed ID: 8809161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Towards a new generation of potential antipsychotic agents combining D2 and 5-HT1A receptor activities.
    Cuisiat S; Bourdiol N; Lacharme V; Newman-Tancredi A; Colpaert F; Vacher B
    J Med Chem; 2007 Feb; 50(4):865-76. PubMed ID: 17300168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New antipsychotic agents with serotonin and dopamine antagonist properties based on a pyrrolo[2,1-b][1,3]benzothiazepine structure.
    Campiani G; Nacci V; Bechelli S; Ciani SM; Garofalo A; Fiorini I; Wikström H; de Boer P; Liao Y; Tepper PG; Cagnotto A; Mennini T
    J Med Chem; 1998 Sep; 41(20):3763-72. PubMed ID: 9748351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-activity relationship studies of CNS agents. Part 24: New analogs of N-tert.-butyl-3-[4-(2-methoxyphenyl)-1-piperazinyl]-2-phenylpropanamide (WAY-100135).
    Boksa J; Klodzińska A; Charakchieva-Minol S; Chojnacka-Wójcik E; Mokrosz JL
    Pharmazie; 1996 Feb; 51(2):72-6. PubMed ID: 8720802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-activity relationships of a series of substituted benzamides: potent D2/5-HT2 antagonists and 5-HT1a agonists as neuroleptic agents.
    Norman MH; Rigdon GC; Hall WR; Navas F
    J Med Chem; 1996 Mar; 39(5):1172-88. PubMed ID: 8676355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contrasting contribution of 5-hydroxytryptamine 1A receptor activation to neurochemical profile of novel antipsychotics: frontocortical dopamine and hippocampal serotonin release in rat brain.
    Assié MB; Ravailhe V; Faucillon V; Newman-Tancredi A
    J Pharmacol Exp Ther; 2005 Oct; 315(1):265-72. PubMed ID: 15987834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antipsychotics differ in their ability to internalise human dopamine D2S and human serotonin 5-HT1A receptors in HEK293 cells.
    Heusler P; Newman-Tancredi A; Loock T; Cussac D
    Eur J Pharmacol; 2008 Feb; 581(1-2):37-46. PubMed ID: 18190908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-activity relationships of a series of novel (piperazinylbutyl)thiazolidinone antipsychotic agents related to 3-[4-[4-(6-fluorobenzo[b]thien-3-yl)-1-piperazinyl]butyl]-2,5,5- trimethyl-4-thiazolidinone maleate.
    Hrib NJ; Jurcak JG; Bregna DE; Burgher KL; Hartman HB; Kafka S; Kerman LL; Kongsamut S; Roehr JE; Szewczak MR; Woods-Kettelberger AT; Corbett R
    J Med Chem; 1996 Sep; 39(20):4044-57. PubMed ID: 8831770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and Pharmacology of the enantiomers of the potential atypical antipsychotic agents 5-OMe-BPAT and 5-OMe-(2,6-di-OMe)-BPAT.
    Homan EJ; Copinga S; Unelius L; Jackson DM; Wikström HV; Grol CJ
    Bioorg Med Chem; 1999 Jul; 7(7):1263-71. PubMed ID: 10465402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of the aliphatic spacer length on the 5-HT1A receptor activity of new arylpiperazines with an indazole system.
    Paluchowska MH; Duszyńska B; Kłodzińska A; Tatarczyńska E
    Pol J Pharmacol; 2000; 52(3):209-16. PubMed ID: 11055578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 9-substituted 1,2,3,4-tetrahydro-beta-carbolin-1-ones, new 5-HT1A and 5-HT2A receptor ligands.
    Mokrosz MJ; Boksa J; Charakchieva-Minol S; Wesołowska A; Borycz J
    Pol J Pharmacol; 1999; 51(4):351-6. PubMed ID: 10540967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis of 3-aryl-1-[(4-phenyl-1-piperazinyl)butyl]indazole derivatives and their affinity to 5-HT1A serotonin and dopamine D1 receptors.
    Andronati S; Sava V; Makan S; Kolodeev G
    Pharmazie; 1999 Feb; 54(2):99-101. PubMed ID: 10084155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential role of 5-HT2 and D2 receptor interaction in the atypical antipsychotic action of the novel succimide derivative, perospirone.
    Ohno Y; Ishida-Tokuda K; Ishibashi T; Sakamoto H; Tagashira R; Horisawa T; Yabuuti K; Matsumoto K; Kawabe A; Nakamura M
    Pol J Pharmacol; 1997 Aug; 49(4):213-9. PubMed ID: 9437764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MP-3022, a new putative antagonist at pre- and postsynaptic 5-HT1A receptors.
    Przegaliński E; Filip M; Bijak M; Wedzony K; Budziszewska B; Tokarski K; Maćkowiak M; Fijał K
    Pol J Pharmacol; 1996; 48(1):13-22. PubMed ID: 9112623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 1,4-Benzoxazin-3(4H)-one derivatives and related compounds as 5-HT1A and 5-HT2A receptor ligands; the effect of the terminal amide fragment on the 5-HT1A/5-HT2A affinity and functional activity.
    Mokrosz MJ; Kowalski P; Kowalska T; Majka Z; Duszyńska B; Charakchieva-Minol S; Szaro A; Tatarczyńska E; Kłodzińska A; Chojnacka-Wójcik E
    Pol J Pharmacol; 1998; 50(4-5):333-40. PubMed ID: 10091718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro profile of the antidepressant candidate OPC-14523 at rat and human 5-HT1A receptors.
    Jordan S; Chen R; Koprivica V; Hamilton R; Whitehead RE; Tottori K; Kikuchi T
    Eur J Pharmacol; 2005 Jul; 517(3):165-73. PubMed ID: 15985260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of linking bridge modifications on the 5-HT1A receptor activity of some 4-(omega-benzotriazol-1-yl)alkyl-1-(2-methoxy-phenyl)piperazines.
    Paluchowska MH; Kłodzińska A; Tatarczyńska E; Szaro A; Chojnacka-Wójcik E
    Pol J Pharmacol; 1998; 50(4-5):341-7. PubMed ID: 10091719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.